Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 10;186(9):E333-9.
doi: 10.1503/cmaj.130720. Epub 2014 Jan 20.

Interpretation of cerebrospinal fluid protein tests in the diagnosis of sporadic Creutzfeldt-Jakob disease: an evidence-based approach

Michael B Coulthart  1 , Gerard H Jansen  2 , Neil R Cashman  2
Affiliations
Review

Interpretation of cerebrospinal fluid protein tests in the diagnosis of sporadic Creutzfeldt-Jakob disease: an evidence-based approach

Michael B Coulthart et al. CMAJ. .
No abstract available

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Effects on diagnostic probabilities of results of cerebrospinal fluid protein tests for 14-3-3 (A), tau (B) and S100B (C) in sporadic Creutzfeldt–Jakob disease (CJD). X: pretest probability (sporadic CJD prevalence); closed and open squares: posttest probability for positive or negative test results, respectively; horizontal bars: 95% confidence interval (CI); vertical dashed lines: diagnostic opinion category (Box 2); numbers at right: size of effect on diagnostic probability in terms of category differences, for negative (Neg) and positive (Pos) test results; numbers in square brackets: effect size with strict application of 95% CI.
Figure 2:
Figure 2:
Pre- and posttest diagnostic probabilities for sporadic Creutzfeldt–Jakob disease (CJD), based on the data of Coulthart and colleagues, for various illustrative concentrations of cerebrospinal fluid tau and S100B protein individually and in combination. X: pretest probability (sporadic CJD prevalence); closed and open squares: posttest probability for positive or negative test results, respectively; horizontal bars: 95% confidence interval (CI); vertical dashed lines: diagnostic opinion category (Box 2); numbers at right: size of effect on diagnostic probabilities in terms of category differences, for negative (Neg) and positive (Pos) test results; numbers in square brackets: effect size with strict application of 95% CI.
See this image and copyright information in PMC

References

    1. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998;95:13363–83 - PMC - PubMed
    1. Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt–Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 2005;64:1586–91 - PubMed
    1. Kovács GG, Puopolo M, Ladogana A, et al. Genetic prion disease: the EUROCJD experience. Hum Genet 2005;118:166–74 - PubMed
    1. Brown P, Brandel JP, Sato T, et al. Iatrogenic Creutzfeldt–Jakob disease, final assessment. Emerg Infect Dis 2012;18:901–7 - PMC - PubMed
    1. Mackay GA, Knight RS, Ironside JW. The molecular epidemiology of variant CJD. Int J Mol Epidemiol Genet 2011;2:217–27 - PMC - PubMed

MeSH terms

Substances

Supplementary concepts